Where it's made
| Factory | Where | Role | Last FDA inspection |
|---|---|---|---|
| Zydus Lifesciences Limited | Ahmedabad, India | Makes it and tests it | Problems found, fixed voluntarilyMar 24, 2023 · 5 inspections |
Recalls
- Feb 24, 2023 · Class III · Zydus Pharmaceuticals (USA) Inc
Failed Impurities/Degradation Specifications: An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e. Beta-lumicolchicine.
Lots: Lot #s: a) E203821, Exp. 05/2024; b) E203822, Exp. 05/2024, E206186, Exp. 10/2024; c) E203820, Exp. 05/2024.
Class I recalls are the most serious; Class III the least. A recall covers specific lots, listed on each recall.
Product details
- Generic drug
- Colchiceine: every company that makes it
- Form
- tablet, oral
- Strength
- 0.6 mg
- Approval
- ANDA ANDA211519
- On the market since
- Jun 12, 2019
- Package NDCs
70710-1351-170710-1351-370710-1351-570710-1351-9- Official label
- DailyMed (National Library of Medicine), updated Oct 4, 2022
Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?